The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

A pooled analysis of five prospective trials showed that stereotactic body radiotherapy (SBRT) was associated with a lower risk for biochemical failure over 10 years vs high-dose rate brachytherapy ...

In men with localized, intermediate-risk prostate cancer, stereotactic body radiation therapy (SBRT) was associated with less toxicity at 2 years but a higher rate of biochemical failure at 3 years ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...

Adding PSMA-based radioligand therapy to metastasis-directed SBRT in men with oligorecurrent prostate cancer delays progression, defined by PSMA PET/CT. As PSMA-targeting RLT improves survival ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

Docetaxel with androgen deprivation therapy (ADT) and radiotherapy (RT) for high-risk localized prostate cancer (HRLPC): An ICECaP individual patient-data (IPD) meta-analysis of randomized controlled ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...

SAN FRANCISCO, September 28, 2025 — A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression ...